Skip to main content
SpringerLink
Log in

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

  • Research Article
  • Published:
Tumor Biology

Abstract

Emerging evidence has shown that p53gene participates in human carcinogenesis as tumor suppressors. Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. It has been suggested that p53 codon72 Arg/Pro polymorphism is associated with susceptibility to hepatocellular carcinoma (HCC). However, published results are inconsistent and inconclusive. To examine the validity of the association between the polymorphism and HCC risk, we performed this meta-analysis. We have conducted a search of case–control studies on the associations of p53 codon72 polymorphism with susceptibility to HCC in PubMed, ScienceDirect, BioMed central, Springer, EBSCO, Wanfang databases, and Chinese National Knowledge Infrastructure databases. A total of 15 studies were identified with 3,704 cases and 4,559 controls for codon72 Arg/Pro polymorphism. The result did support a significant genetic association between Pro allele and susceptibility to HCC in all the genetic models. Similarly, subgroup analysis showed significant associations between the Arg/Pro polymorphism and susceptibility to HCC when stratifying by race, gender, source of controls, and hepatitis virus infection status. This meta-analysis suggests that p53 codon72 Arg/Pro polymorphism may be associated with the risk of HCC, especially in subgroup analysis of Asian and Caucasian population, hospital-based population, the female, and the individuals infected with hepatitis virus. However, well-designed studies based on different ethnic groups with larger sample size and more detailed data are needed to confirm these conclusions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

CNKI:

Chinese National Knowledge Infrastructure

HBV:

Hepatitis B virus

HCV:

Hepatitis C virus

HWE:

Hardy-Weinberg equilibrium

CIs:

Confidence intervals

PCR-RFLP:

Polymerase chain reaction–restriction fragment length polymorphism

PCR-ASP:

Polymerase chain reaction–allele specific polymerase chain reaction

PCR-SSCP:

Polymerase chain reaction-single strand conformation polymorphism analysis

P H :

Between-study heterogeneity

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342(2):223–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

    Article  CAS  PubMed  Google Scholar 

  4. Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.

    CAS  PubMed  Google Scholar 

  5. Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33(4):927–33.

    Article  CAS  PubMed  Google Scholar 

  6. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. Tp53 and liver carcinogenesis. Hum Mutat. 21:201–16.

  7. Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.

    Article  CAS  PubMed  Google Scholar 

  8. Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60.

    Article  CAS  PubMed  Google Scholar 

  9. Mohana Devi S, Balachandar V, Arun M, Suresh Kumar S, Balamurali Krishnan B, Sasikala K. Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci. 2013;58(3):759–67.

    Article  CAS  PubMed  Google Scholar 

  10. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37(9):748–54.

    Article  CAS  PubMed  Google Scholar 

  11. Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. P53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Mol Biol Rep. 2012;39:1639–47.

    Article  CAS  PubMed  Google Scholar 

  12. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7.

    Article  PubMed  Google Scholar 

  13. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29(6):1192–6.

    Article  CAS  PubMed  Google Scholar 

  14. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11(2):289–92.

    CAS  PubMed  Google Scholar 

  15. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193(2):199–205.

    Article  CAS  PubMed  Google Scholar 

  16. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29(3):697–702.

    Article  CAS  PubMed  Google Scholar 

  17. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU. Codon 72 polymorphism of p53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 208:75–79.

  18. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6(13).

  19. Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int. 2011;5(3):814–21.

    Article  PubMed  Google Scholar 

  20. Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4(1):71–81.

    Article  CAS  PubMed  Google Scholar 

  21. Peng TYL, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single nucleotide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313–4.

    Google Scholar 

  22. Zhang YYYH, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189–93.

    CAS  Google Scholar 

  23. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826

    Google Scholar 

  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429–31.

    Article  CAS  PubMed  Google Scholar 

  27. Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol. 2003;9(6):1202–7.

    CAS  PubMed  Google Scholar 

  28. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196–9.

    Article  CAS  PubMed  Google Scholar 

  29. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25(25):3489–500.

    Article  CAS  PubMed  Google Scholar 

  30. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95–107.

    Article  CAS  PubMed  Google Scholar 

  31. Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol. 2011;17(9):1211–8.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Ding C, Yu H, et al. Tp53 codon 72 polymorphism with hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2012;40:446–54.

    Article  CAS  PubMed  Google Scholar 

  33. Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2013;34(3):1451–9.

    Article  CAS  PubMed  Google Scholar 

  34. Puente XS, Velasco G, Gutiérrez-Fernández A, Bertranpetit J, King MC, López-Otín C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics;7(15).

  35. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78 Suppl 1:172–9.

    Article  CAS  PubMed  Google Scholar 

  36. Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 2012;228(2):216–29.

    Article  CAS  PubMed  Google Scholar 

  37. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166–76.

    Article  CAS  PubMed  Google Scholar 

  38. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56–61.

    Article  PubMed  Google Scholar 

Download references

Grant support

We have no support or funding to report.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Geriatrics, Changzhou NO 2 People’s Hospital, Affiliated Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou, 213003, Jiangsu Province, China

    Surong Hu, Jingting Yang & Miao Hu

  2. Kunshan Agency for Public Health Inspection, Suzhou, China

    Lianying Zhao

Authors
  1. Surong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lianying Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingting Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miao Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miao Hu.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 48 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, S., Zhao, L., Yang, J. et al. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumor Biol. 35, 3647–3656 (2014). https://doi.org/10.1007/s13277-013-1483-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1483-7

Keywords

Search

Navigation